European Market for Coronary Stents – Frost & Sullivan 

Press Release

Keywords: European, coronary stents, minimally invasive surgery, drug eluting stents, DES, bare metal stents, BMS, interventional cardiology, bioabsorbable stents, alternative treatments, laser angioplasty, drug therapy, stenosis, thrombogenocity, thrombosis

Results of the EVEREST (Evaluation of Endoluminal Radiation in Elective Stenting) Trial

Purpose:  This randomized study was designed to compare the efficacy of high-dose coronary β-radiation after intravascular ultrasound-(IVUS-)guided direct stenting with sham treatment in patients with de novo lesions.

Key Words:  Intracoronary brachytherapy - In-stent restenosis - De novo lesions

Merit’s products address the needs of cardiologists and radiologists around the world, enabling them to perform diagnostic and interventional procedures such as angiography, angioplasty, stent placement, AAA (stent grafts), discography, thrombolysis and other procedures. Merit’s product lines include balloon inflation devices and accessories, diagnostic and therapeutic catheters and guide wires, pressure monitoring disposables, fluid delivery systems, medication syringes, safety products, and needles. Merit currently offers over 2,000 FDA-cleared devices, participating in a market estimated to be over $1 billion annually.

Home page

In Italy, revascularization interventions increased from 44,600 in 1996 to more than 100,000 in 2001. In particular, the occurrence of percutaneous transluminal coronary angioplasty (PTCA) increased from 239 cases per million population in 1994 to about 1300 cases per million population in 2001. This trend has caused a concomitant increase in revascularization costs, which have doubled in few years, rising from €421 millions in 1996 to €850 millions in 2001. In 2001, PTCA amounted to 55% of total cost of revascularizations.

Abstract

Percutaneous Transluminal Coronary Angioplasty (PTCA) – often abbreviated to angioplasty – is a procedure to re-open a narrowed coronary artery. Watch how this procedure opens arteries.

High quality PTCA procedure 3D animation

One more explain for patients what is angioplasty.

Link

Strong profits, low interest rates, and hordes of cash have sparked a wave of mergers that underlie Boston Scientific’s battle to buy a rival medical device maker.

Merger and acquisitions last year topped $1 trillion nationally, the most since 2000, and $170 billion in New England, the most since 1998, according to Thomson Financial. This year, US mergers are off to one of the fastest starts ever, with $46 billion in deals announced in the first 11 days, according to Thomson.

Full news

Guidant Corp.’s board on Friday accepted a sweetened, $24.2 billion buyout offer from Johnson & Johnson, rejecting a richer Boston Scientific Corp. bid for the troubled cardiac device maker.
J&J agreed to pay $40.52 in cash and 0.493 share of Johnson & Johnson stock, with a total value of $71 a share, the companies said. Boston Scientific raised its offer Thursday by $1 a share to $73, half in cash and half stock, totaling about $25 billion.
Full news

The story about SilverHawk Plaque Excision System.

Clinical Outcomes

After more than a year of courtship, Johnson & Johnson has again sweetened its bid for Guidant but rival Boston Scientific Corp. isn’t ceding ground in its quest to acquire the medical device maker.

Guidant Corp.’s board unanimously endorsed a new, $23.2 billion bid from J&J late Wednesday and recommended its shareholders approve it Jan. 31 when they gather to vote. Boston Scientific immediately said it would continue working to advance its own $25 billion offer.

Full news

Daiichi Sankyo has signed a deal worth up to $340 million with KAI Pharmaceuticals for the global development and commercialization of KAI-9803, an experimental treatment for the prevention of myocardial tissue death. While this could represent an astute move by Daiichi to boost its cardio business, it could also be seen as a desperate pipeline-filling attempt following CS-505’s recent failure.

Full news

Surgeons at NewYork-Presbyterian Hospital/Weill Cornell Medical Center are the first in the New York City metropolitan area to successfully implant into the brain arteries a new stent specifically designed to treat high-risk stroke patients who have not previously responded to medical therapy. The Wingspan™ Stent System is used for those individuals diagnosed with intracranial atherosclerotic disease (ICAD) — excess plaque buildup in the brain arteries.

Full news

KAI Pharmaceuticals, Inc., a privately held biotechnology company, and DAIICHI SANKYO COMPANY, LIMITED today announced that Sankyo Company, Limited, a wholly owned subsidiary of DAIICHI SANKYO, and KAI Pharmaceuticals have entered an agreement for the global development and commercialization of KAI-9803, with an initial focus on cardiovascular disease. KAI-9803, a delta Protein Kinase C (delta PKC) inhibitor, is a first-in-class agent for the prevention of myocardial tissue death and associated congestive heart failure in acute myocardial infarction patients undergoing revascularization procedures.

Full Press Release

BACKGROUND: Bleeding is a common and costly complication of percutaneous coronary intervention (PCI). Little is known about the risk factors for bleeding complications.

OBJECTIVE: To report our PCI-related observations from a single institution and use the information to establish risk factors for short-term bleeding complications, with special focus on examining the importance of renal function.

METHODS: A retrospective record review was conducted of the admission of 300 patients grouped according to antithrombotic regimen: unfractionated heparin alone (n = 187), bivalirudin (n = 26), and glycoprotein IIb/IIIa antagonist plus heparin (n = 103). Bleeding and ischemic outcomes were tracked. A model was constructed to predict independent bleeding risk factors.

Published in The Annals of Pharmacotherapy

Key Words: bivalirudin, glycoprotein IIb/IIIa antagonist, heparin

PURPOSE: The aim of this study was to evaluate virtual reality (VR) simulation for endovascular training of surgeons inexperienced in this technique. METHODS: Twenty consultant vascular surgeons were divided into those who had performed >50 endovascular procedures (e.g. aortic and carotid stent) as primary operator (n=8), and those having performed <10 procedures (n=12). To test for endovascular skill rather than procedural knowledge, all subjects performed a renal artery balloon angioplasty and stent procedure. The simulator uses real tools with active force feedback, and provides a realistic image of the virtual patient. Surgeons with endovascular skills performed two repetitions and those without completed six repetitions of the same task. The simulator recorded time taken for the procedure, the amount of contrast fluid used and total fluoroscopy time.

PubMed Abstract